Review
Open access
Oct 2026
GLP-1 receptor agonists as potential disease-modifying agents in Parkinson’s and Alzheimer’s disease: mechanisms, clinical trial evidence, and the neuroprotection horizon
Although the mechanistic and epidemiological rationale for GLP-1 RAs in neurodegeneration remains biologically plausible, current trial evidence does not yet support their use outside clinical trials, irrespective of comorbid diabetes status; future studies should prioritize earlier intervention, biomarker-guided patie...
Mohamed Alsharif, Omran Shrebaty, Mohammad Ammar Aloudah et al.
· Frontiers in Aging Neuroscie... · 0 citations